Compare AbCellera Biologics Inc (ABCL) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Fidelity National Information Servcs Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Fidelity National Information Servcs Inc trades at $41.13 (market cap $22.02B). The key difference: Fidelity National Information Servcs Inc is far larger — about 9.4× AbCellera Biologics Inc's market cap, and Fidelity National Information Servcs Inc pays a 3.94% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FIS | |
|---|---|---|
Market Cap | $2.35B | $22.02B |
Sector | Health | Technology |
52-Week High | $8.12 | $81.94 |
52-Week Low | $2.78 | $37.72 |
Enterprise Value | $1.99B | $42.41B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
FIS trades at $42.6, up 1.91% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with 2025 revenue of $10.68B and a net income margin of 23.35%, supported by a low P/E of 8. Recent news highlights strategic wins, including partnerships with Frankfurt International Bank and First Commerce Bank for cloud-native banking solutions, reinforcing its competitive positioning in financial technology.
The outlook is positive with a consensus price target of $55.40, implying significant upside. Key opportunities include continued revenue growth and margin expansion, but risks involve a high debt load and macroeconomic pressures on lending markets. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on debt management and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
